Upfront License Fee was Seres Therapeutics’s largest revenue line in fiscal 2016, bringing in $11.77M of $21.77M (54%).
| Type Of Arrangement | FY 2016 |
|---|---|
| Upfront License Fee | $11.77M |
| Phase 3 | $10.00M |
| Total | $21.77M |
Seres Therapeutics brought in $21.77M from its two revenue lines in fiscal 2016, the year ended December 31, 2016. Upfront License Fee was the largest at $11.77M (54.1%), ahead of Phase 3 at $10.00M (45.9%).
Seres Therapeutics (MCRB) reports its revenue by type of arrangement. In fiscal 2016, Upfront License Fee was its largest revenue line, bringing in $11.77M (54.1% of the total), followed by Phase 3 at $10.00M (45.9%).
Upfront License Fee was Seres Therapeutics' largest revenue line in fiscal 2016, bringing in $11.77M, or 54.1% of the $21.77M total across its two revenue lines.
Every figure comes from Seres Therapeutics' annual financial filings, as reported. Each line keeps the name Seres Therapeutics gives it, and years follow its fiscal calendar.
Seres Therapeutics' revenue by type of arrangement goes back to fiscal 2016, with figures through fiscal 2016. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.